Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAV, CFG

/R E P E A T -- Notice to the media - Ministers and Government of Canada officials to hold a news conference on coronavirus disease (COVID-19)/


OTTAWA, April 3, 2020 /CNW/ - Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19).

Date
April 3, 2020

Time
12:00 PM (EDT)

Location

West Block, Room 225
Parliament Hill
Wellington Street, Ottawa, Ontario

The media availability will also be held by teleconference.
Toll-free (Canada/US) dial-in number: 1-866-206-0153
Local dial-in number: 613-954-9003

Passcode: 1622050#

Twitter: @GovCanHealth
Facebook: Healthy Canadians

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 08:45
The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. This market research report provides key insights into the industry's rapid growth...

at 08:40
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024...

at 08:38
HFA Architecture + Engineering has expanded its healthcare design team with the addition of Principal and Healthcare Practice Leader Paul Sabal (AIA, ACHA, NCARB, LEED AP).  Sabal is a registered architect and interior designer with more than four...

at 08:35
NanoVibronix, Inc. ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...



News published on and distributed by: